JP2017218380A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017218380A5 JP2017218380A5 JP2016111280A JP2016111280A JP2017218380A5 JP 2017218380 A5 JP2017218380 A5 JP 2017218380A5 JP 2016111280 A JP2016111280 A JP 2016111280A JP 2016111280 A JP2016111280 A JP 2016111280A JP 2017218380 A5 JP2017218380 A5 JP 2017218380A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- irradiation
- subcutaneous tumor
- nicaraben
- physiological saline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000035492 administration Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- KTXBOOWDLPUROC-UHFFFAOYSA-N N-[2-(pyridine-3-carbonylamino)propyl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C)CNC(=O)C1=CC=CN=C1 KTXBOOWDLPUROC-UHFFFAOYSA-N 0.000 description 2
- 229950009737 Nicaraven Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- JKOQGQFVAUAYPM-UHFFFAOYSA-N Amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960001097 Amifostine Drugs 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
Description
４．薬剤の投与
図１に示すように、放射線照射およびガン細胞静脈内注射の直前（３０分内）にニカラベン（Ｎｉｃａｒａｖｅｎ）（１００ｍｇ／ｋｇ）あるいはアミフォスチン（Ａｍｉｆｏｓｔｉｎｅ）（５０ｍｇ／ｋｇ）を０．２ｍＬの生理食塩水に溶かして腹腔内注射した。対照治療としては０．２ｍＬの生理食塩水のみ、腹腔内注射した。また、薬剤の投与は放射線照射の当日から毎日１回で、計７回の投与を行った。なおニカラベンは中外製薬株式会社から提供されたニカラベン原末を使用した。
4). Drug administration
As shown in FIG. 1, immediately before irradiation and intravenous injection of cancer cells (within 30 minutes), Nicaraven (100 mg / kg) or Amifostine (50 mg / kg) in 0.2 mL of physiological saline It was dissolved in and injected intraperitoneally. As a control treatment, only 0.2 mL of physiological saline was injected intraperitoneally. In addition, the drug was administered once a day from the day of irradiation, for a total of 7 administrations. For Nicaraben, Nicaraben bulk powder provided by Chugai Pharmaceutical Co., Ltd. was used.
＜試験例２＞自発肺内腫瘍形成（転移）実験
１．実験動物
雄性マウス（Ｃ５７ＢＬ／６、９〜１０週齢、体重20〜28ｇ）を実験に用いた。
２．皮下腫瘍の作製
マウス肺ガン細胞（ＬＬＣ、１ｘ１０６ｃｅｌｌｓ／０．１ｍｌ ＰＢＳ）をマウスの背部に皮下注射し、皮下腫瘍モデルを作製した。
３．放射線照射
皮下腫瘍作製後１０日目にマウスの胸部のみに５ＧｙのＸ線放射線照射を行った（１．５Ｇｙ／ｍｉｎ、鉛で他の部位を保護）。
４．皮下腫瘍の切除
皮下腫瘍作製後１５日目（Ｘ線放射線照射後５日目）に皮下腫瘍の摘出手術を行った。
５．薬剤の投与
図４に示すように、放射線照射の直前（３０分内）にニカラベン（Ｎｉｃａｒａｖｅｎ）（１００ｍｇ／ｋｇ）を０．２ｍＬの生理食塩水に溶かして腹腔内注射した。対照治療としては０．２ｍＬの生理食塩水のみ、腹腔内注射する。また、薬剤の投与は放射線照射の当日から毎日１回で、計７回の投与を行う。なおニカラベンは中外製薬株式会社から提供されたニカラベン原末を使用した。
Test Example 2 Spontaneous lung tumor formation (metastasis) experiment Experimental animals Male mice (C57BL / 6, 9-10 weeks old, body weight 20-28 g) were used in the experiments.
2. Production of Subcutaneous Tumor Mouse lung cancer cells (LLC, 1 × 10 6 cells / 0.1 ml PBS) were injected subcutaneously into the back of the mouse to produce a subcutaneous tumor model.
3. Irradiation On the 10th day after preparation of the subcutaneous tumor, only the chest of the mouse was irradiated with 5 Gy of X-rays (1.5 Gy / min, other sites were protected with lead).
4). Resection of subcutaneous tumor The surgical removal of the subcutaneous tumor was performed on the 15th day (5 days after the X-ray irradiation) after preparation of the subcutaneous tumor.
5. 4. Administration of drug As shown in FIG. 4, immediately before irradiation (within 30 minutes), Nicaraven (100 mg / kg) was dissolved in 0.2 mL of physiological saline and injected intraperitoneally. As a control treatment, only 0.2 mL of physiological saline is injected intraperitoneally. In addition, the drug is administered once a day from the day of irradiation, for a total of 7 administrations. For Nicaraben, Nicaraben bulk powder provided by Chugai Pharmaceutical Co., Ltd. was used.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016111280A JP6682116B2 (en) | 2016-06-02 | 2016-06-02 | Cancer metastasis inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016111280A JP6682116B2 (en) | 2016-06-02 | 2016-06-02 | Cancer metastasis inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017218380A JP2017218380A (en) | 2017-12-14 |
| JP2017218380A5 true JP2017218380A5 (en) | 2018-09-13 |
| JP6682116B2 JP6682116B2 (en) | 2020-04-15 |
Family
ID=60658359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016111280A Active JP6682116B2 (en) | 2016-06-02 | 2016-06-02 | Cancer metastasis inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6682116B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024024923A1 (en) * | 2022-07-28 | 2024-02-01 | 株式会社サイエンステクノロジーインタラクト | Medicine for treating cancer |
-
2016
- 2016-06-02 JP JP2016111280A patent/JP6682116B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017516775A (en) | Combination therapy for the treatment of cancer | |
| JP2016528162A5 (en) | ||
| JP2010531877A5 (en) | ||
| JP2016028090A5 (en) | ||
| RU2010113989A (en) | APPLICATION OF A PEPTIDE AS A THERAPEUTIC | |
| JP2019512495A5 (en) | ||
| JP2016526531A5 (en) | ||
| JP2017218380A5 (en) | ||
| RU2012108144A (en) | ANTI-CANCER THERAPY DIRECTED AGAINST CANCER STEM CELLS AND CANCER FORMS RESISTANT TO TREATMENT BY MEDICINES | |
| JP2020502182A5 (en) | ||
| JP2016510040A5 (en) | ||
| WO2011149250A3 (en) | Tricarbonyl technetium-99m or rhenium-188 label ring rgd derivative, a preparation method thereof, and a pharmaceutical composition containing the derivative as an active ingredient for use in the diagnosis or treatment of angiogenesis-related diseases | |
| JP2021509916A5 (en) | ||
| Stamets | Trametes versicolor (Turkey Tail Mushrooms) and the treatment of breast cancer | |
| Voulgari et al. | Transfusion-related acute lung injury during intravenous immunoglobulin treatment | |
| JP2018199726A5 (en) | ||
| JPWO2014050912A1 (en) | Liquid medicine dissolved with carbon dioxide and therapeutic method using the same | |
| CN103520161A (en) | Application of levosimendan in preparation of drug for cardio-pulmonary resuscitation after cardiac arrest caused by amide-type local anesthetics and cardio-pulmonary resuscitation therapy | |
| Evstigneev et al. | Photodynamic therapy and diagnosis of lower lip cancer with photosense | |
| KR20210022577A (en) | Supernatant from co-culture of macrophages and irradiated leukocytes for controlling tumor progression or for restoring anti-tumor immunity | |
| Shojaku | Various toxicities in an elderly patient following intra-arterial administration: case report | |
| RU2554750C1 (en) | Method of lung cancer treatment | |
| Kotopoulis et al. | Ultrasound sonoporation in pancreatic adenocarcinoma | |
| RU2021107897A (en) | MEDICINE FOR RELIEF AND/OR SUPPRESSION OF PERIPHERAL NEUROPATHY CAUSED BY ANTI-CANCER AGENT | |
| US20190290657A1 (en) | Method for treating conditions associated with hyperproliferating cells comprising combined administration of a cannabinoid receptor agonist and radiation therapy |